The way cancer cells utilize fats – a crucial energy source for healthy cells – is increasingly becoming a focal point in cancer research. Understanding this metabolic process could unlock new therapeutic avenues, particularly for aggressive cancers like pancreatic cancer and metastatic melanoma. Recent research, spearheaded by a team at the IFOM ETS-The AIRC Institute of Molecular Oncology in Milan, Italy, has identified the enzyme BACE2 as a key regulator of lipid entry into cancer cells, positioning it as a potential target for future cancer treatments. This discovery highlights the growing field of precision oncology, where treatments are tailored to the unique molecular characteristics of each tumor.
For rapidly growing cancer cells, lipids aren’t just an energy source; they’re also essential building blocks for cellular components. However, the way tumors access and process these fats isn’t uniform. As Angela Bachi, principal investigator at IFOM and lead researcher on the study, explains, “Tumors behave very differently depending on their molecular characteristics.” This variability underscores the importance of precision medicine, an approach that aims to identify these characteristics and develop customized treatments. Bachi and her team began investigating these differences in tumor aggressiveness several years ago, focusing on protein levels within cancer cells.
BACE2: A Gatekeeper of Lipid Metabolism in Cancer
The research, published in the Journal of Experimental & Clinical Cancer Research, revealed that certain tumors express high levels of the protein BACE2 and exhibit faster proliferation rates. Initially known for its role in neurodegenerative diseases like Alzheimer’s, the function of BACE2 in cancer is a relatively recent area of study. The IFOM team’s perform began with melanoma models and expanded to include pancreatic cancer, observing a consistent correlation between elevated BACE2 levels and increased tumor growth. The study details how BACE2 functions as a “gatekeeper,” maintaining a balance of lipid levels between the inside and outside of cells.
Normally, BACE2 senses the amount of fat in the surrounding environment and regulates its absorption by cells. However, in cancer cells with high BACE2 levels, this regulation is altered. The enzyme, through its control of lipid transporters, prevents an excessive buildup of fats within the cell, which would otherwise be toxic. This seemingly paradoxical mechanism allows cancer cells to maintain a steady supply of lipids without succumbing to the damaging effects of lipid overload. Angela Bachi, who earned her PhD in analytical biochemistry at the Mario Negri Institute in Milan in 1990, has dedicated her career to understanding the complexities of cellular metabolism and applying that knowledge to cancer research. She became a principal investigator at IFOM in May 2013, bringing with her expertise in biomolecular mass spectrometry developed during postdoctoral studies at the EMBL in Heidelberg.
“Intoxicating” Cancer Cells: A Novel Therapeutic Approach
Driven by these findings, Bachi’s team investigated whether disrupting this BACE2-mediated mechanism could have a therapeutic effect. Experiments involving blocking the enzyme in laboratory cell models revealed a surprising outcome: “inhibiting BACE2 leads to a kind of intoxication of the tumor,” Bachi explained. By blocking BACE2, cancer cells, driven by their high demand for lipids, absorb an excessive amount, exceeding their capacity to metabolize them. This leads to metabolic stress and ultimately reduces tumor growth. “Too much of a good thing is bad for tumors, too,” Bachi commented, highlighting the specificity of this effect. Because it exploits the cancer cells’ dependence on lipids, the approach primarily targets cells with high BACE2 expression, potentially minimizing harm to healthy tissues.
This research builds upon the growing understanding of cancer metabolism, a field that recognizes cancer cells’ altered metabolic pathways as potential therapeutic vulnerabilities. The American Cancer Society notes that cancer cells often exhibit increased glucose uptake and altered lipid metabolism to support their rapid growth and proliferation. Understanding these metabolic differences is crucial for developing targeted therapies.
The Role of Precision Medicine and Future Directions
While these findings are promising, Bachi emphasizes that the results are currently limited to laboratory models and cannot yet be directly translated to patient treatment. “It is still early to define a connection between diet and the functioning of BACE2,” she stated. Her team plans to further investigate whether different types of fatty acids – saturated or unsaturated – can modulate BACE2 activity. This line of inquiry could potentially inform dietary recommendations for patients undergoing cancer treatment, although more research is needed.
Currently, the research team is continuing to study BACE2 in more complex laboratory models that more closely resemble real-world conditions, such as three-dimensional cell cultures. They are also exploring the potential of BACE2 inhibitors, potentially in combination with other medications, to enhance their effectiveness. A key area of ongoing investigation is whether dietary factors can influence BACE2 activity and the therapeutic effects of its inhibition. The IFOM research group, led by Bachi, is also investigating whether BACE2 functions similarly in other cancer types, expanding the potential scope of this therapeutic strategy.
Bachi’s extensive publication record – exceeding 100 publications in international scientific journals – demonstrates her commitment to advancing the field of proteomics and its application to cancer research. Her work at IFOM, as detailed on the IFOM website, focuses on applying and expanding modern quantitative proteomics to understand cancer biology. She also holds a position as Principal Investigator, Proteomics Lab, and Head of Proteomics and Metabolomics Facility at the ICGEB, as noted on the ICGEB website.
Key Takeaways
- BACE2 as a Target: The enzyme BACE2 regulates lipid entry into cancer cells and is emerging as a potential therapeutic target for cancers like pancreatic cancer and melanoma.
- Metabolic Stress: Blocking BACE2 can lead to metabolic stress in cancer cells, hindering their growth by disrupting lipid metabolism.
- Precision Medicine Approach: This research underscores the importance of precision medicine, tailoring treatments to the unique molecular characteristics of individual tumors.
- Further Research Needed: While promising, these findings are currently limited to laboratory models and require further investigation in animal models and human clinical trials.
The next steps for Bachi’s team involve testing BACE2 inhibitors in animal models and, eventually, conducting clinical trials to assess their safety and efficacy in humans. The research team is also actively seeking funding to support these crucial next phases of investigation. The potential for a novel therapeutic strategy targeting lipid metabolism in cancer offers a glimmer of hope for patients battling these challenging diseases. Readers interested in learning more about cancer research and precision medicine are encouraged to visit the AIRC website for further information and resources.
What are your thoughts on this new approach to cancer treatment? Share your comments below, and please share this article with anyone who might find it informative.